(MDXG) MiMedx - Overview
Stock: Placental Allografts, Amniotic, Surgical, Wound
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 43.3% |
| Relative Tail Risk | -9.66% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.27 |
| Alpha | -55.57 |
| Character TTM | |
|---|---|
| Beta | 0.727 |
| Beta Downside | 0.724 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.03% |
| CAGR/Max DD | 0.04 |
Description: MDXG MiMedx January 20, 2026
MiMedx Group, Inc. (NASDAQ: MDXG) manufactures and distributes placental-derived allografts for wound-care, burn, and surgical applications. Using its proprietary PURION aseptic-processing and terminal-sterilization platform, the firm converts human placental membranes, umbilical cords, and placental discs into products that retain native cytokines, chemokines, and growth factors. Its core wound-care lineup (EPIFIX, EPICORD, EPIEFFECT) is sized to minimize waste, while surgical offerings (AMNIOFIX, AMNIOEFFECT) target lower-extremity repair, plastic, vascular, and orthopedic procedures. Sales are executed through a direct force, independent agents, and distributors across the United States, complemented by a strategic alliance with Vaporox, Inc. for wound-care promotion.
Recent operational data (FY 2023) show revenue of roughly $250 million, up ~20 % year-over-year, driven by expanding adoption of chronic-wound therapies amid an aging U.S. population. Gross margins have hovered near 70 %, reflecting the high-value nature of biologic grafts and the efficiency of the PURION process. The company holds approximately $150 million in cash and short-term investments, providing runway for R&D and potential acquisitions, while the broader regenerative-medicine sector is projected to grow at a CAGR of 12 % through 2030, fueled by rising diabetes-related wound incidence and favorable Medicare reimbursement trends.
For a deeper quantitative assessment, you may find ValueRay’s platform useful for drilling into MDXG’s financials and peer benchmarks.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 40.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA 1.28 > 1.0 |
| NWC/Revenue: 49.92% < 20% (prev 37.98%; Δ 11.94% < -1%) |
| CFO/TA 0.21 > 3% & CFO 67.8m > Net Income 40.8m |
| Net Debt (-123.9m) to EBITDA (70.1m): -1.77 < 3 |
| Current Ratio: 4.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (149.7m) vs 12m ago 0.90% < -2% |
| Gross Margin: 81.99% > 18% (prev 0.83%; Δ 8116 % > 0.5%) |
| Asset Turnover: 139.8% > 50% (prev 140.6%; Δ -0.76% > 0%) |
| Interest Coverage Ratio: 12.98 > 6 (EBITDA TTM 70.1m / Interest Expense TTM 4.27m) |
Altman Z'' 4.01
| A: 0.62 (Total Current Assets 254.1m - Total Current Liabilities 57.7m) / Total Assets 319.0m |
| B: -0.18 (Retained Earnings -57.9m / Total Assets 319.0m) |
| C: 0.20 (EBIT TTM 55.4m / Avg Total Assets 281.4m) |
| D: -0.72 (Book Value of Equity -57.7m / Total Liabilities 80.0m) |
| Altman-Z'' Score: 4.01 = AA |
Beneish M -2.97
| DSRI: 1.26 (Receivables 78.2m/54.0m, Revenue 393.4m/342.8m) |
| GMI: 1.02 (GM 81.99% / 83.26%) |
| AQI: 0.68 (AQ_t 0.17 / AQ_t-1 0.26) |
| SGI: 1.15 (Revenue 393.4m / 342.8m) |
| TATA: -0.08 (NI 40.8m - CFO 67.8m) / TA 319.0m) |
| Beneish M-Score: -2.97 (Cap -4..+1) = A |
What is the price of MDXG shares?
Over the past week, the price has changed by -6.23%, over one month by -21.48%, over three months by -33.91% and over the past year by -41.80%.
Is MDXG a buy, sell or hold?
- StrongBuy: 5
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the MDXG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.4 | 109.3% |
| Analysts Target Price | 10.4 | 109.3% |
| ValueRay Target Price | 4.8 | -3.6% |
MDXG Fundamental Data Overview February 03, 2026
P/E Forward = 19.5313
P/S = 1.9235
P/B = 3.1858
P/EG = 2.97
Revenue TTM = 393.4m USD
EBIT TTM = 55.4m USD
EBITDA TTM = 70.1m USD
Long Term Debt = 16.8m USD (from longTermDebt, last quarter)
Short Term Debt = 1.38m USD (from shortTermDebt, last quarter)
Debt = 18.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -123.9m USD (from netDebt column, last quarter)
Enterprise Value = 632.9m USD (756.8m + Debt 18.2m - CCE 142.1m)
Interest Coverage Ratio = 12.98 (Ebit TTM 55.4m / Interest Expense TTM 4.27m)
EV/FCF = 9.96x (Enterprise Value 632.9m / FCF TTM 63.5m)
FCF Yield = 10.04% (FCF TTM 63.5m / Enterprise Value 632.9m)
FCF Margin = 16.15% (FCF TTM 63.5m / Revenue TTM 393.4m)
Net Margin = 10.38% (Net Income TTM 40.8m / Revenue TTM 393.4m)
Gross Margin = 81.99% ((Revenue TTM 393.4m - Cost of Revenue TTM 70.9m) / Revenue TTM)
Gross Margin QoQ = 83.54% (prev 81.05%)
Tobins Q-Ratio = 1.98 (Enterprise Value 632.9m / Total Assets 319.0m)
Interest Expense / Debt = 4.31% (Interest Expense 785.0k / Debt 18.2m)
Taxrate = 26.70% (6.10m / 22.8m)
NOPAT = 40.6m (EBIT 55.4m * (1 - 26.70%))
Current Ratio = 4.41 (Total Current Assets 254.1m / Total Current Liabilities 57.7m)
Debt / Equity = 0.08 (Debt 18.2m / totalStockholderEquity, last quarter 238.9m)
Debt / EBITDA = -1.77 (Net Debt -123.9m / EBITDA 70.1m)
Debt / FCF = -1.95 (Net Debt -123.9m / FCF TTM 63.5m)
Total Stockholder Equity = 212.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.51% (Net Income 40.8m / Total Assets 319.0m)
RoE = 19.18% (Net Income TTM 40.8m / Total Stockholder Equity 212.9m)
RoCE = 24.12% (EBIT 55.4m / Capital Employed (Equity 212.9m + L.T.Debt 16.8m))
RoIC = 17.55% (NOPAT 40.6m / Invested Capital 231.4m)
WACC = 8.46% (E(756.8m)/V(775.0m) * Re(8.59%) + D(18.2m)/V(775.0m) * Rd(4.31%) * (1-Tc(0.27)))
Discount Rate = 8.59% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.55%
[DCF Debug] Terminal Value 79.77% ; FCFF base≈56.3m ; Y1≈69.5m ; Y5≈118.3m
Fair Price DCF = 13.18 (EV 1.83b - Net Debt -123.9m = Equity 1.95b / Shares 148.1m; r=8.46% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 56.79 | EPS CAGR: 111.9% | SUE: -1.10 | # QB: 0
Revenue Correlation: 94.02 | Revenue CAGR: 14.97% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-03-31): EPS=-0.01 | Chg30d=-0.030 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=0.12 | Chg30d=-0.125 | Revisions Net=-2 | Growth EPS=-71.4% | Growth Revenue=-2.8%